CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

CARsgen makes history as China approves world's first CAR-T therapy for solid tumors

CARsgen gets first CAR-T approval for solid tumors from China's NMPA, median PFS 3.25 vs 1.77 months (gastric cancer). Validates cell therapy for solid tumors and signals Chinese biotech maturity; reshapes global licensing partnerships and biotech investment strategy.